James W. Antoon, Ph.D.
Affiliations: | 2010 | Pharmacology | Tulane University, New Orleans, LA, United States |
Area:
Pharmacology, Molecular Biology, Medicine and SurgeryGoogle:
"James Antoon"Parents
Sign in to add mentor| Barbara S. Beckman | grad student | 2010 | Tulane | |
| (The ceramide-sphingosine-1-phosphate rheostat as a therapeutic target in endocrine and chemotherapy resistant breast cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gestaut MM, Antoon JW, Burow ME, et al. (2014) Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival. Pharmacological Reports : Pr. 66: 174-8 |
| Ponnapakam AP, Liu J, Bhinge KN, et al. (2014) 3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. Bioorganic & Medicinal Chemistry. 22: 1412-20 |
| Martin EC, Elliott S, Rhodes LV, et al. (2014) Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 53: 38-48 |
| White MD, Chan L, Antoon JW, et al. (2013) Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Research. 33: 3573-9 |
| Antoon JW, Martin EC, Lai R, et al. (2013) MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. Plos One. 8: e69291 |
| Antoon JW, Nitzchke AM, Martin EC, et al. (2013) Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology. 42: 1139-50 |
| Antoon JW, Bratton MR, Guillot LM, et al. (2012) Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. American Journal of Cancer Research. 2: 446-58 |
| Antoon JW, White MD, Driver JL, et al. (2012) Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer. Experimental Biology and Medicine (Maywood, N.J.). 237: 832-44 |
| Antoon JW, Lai R, Struckhoff AP, et al. (2012) Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific Reports. 2: 539 |
| Antoon JW, Bratton MR, Guillot LM, et al. (2012) Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation. Cancer Biology & Therapy. 13: 1026-33 |